Payment overview · 2025
General Payments
$628.12
44 reported records · 7 companies
Healthcare provider profile · identity verified
Emily A Comstock, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · GREAT FALLS, MT · NPI 1578514758
Verified facts
What the public records show
CMS Open Payments records show Emily A Comstock, PAC received $628.12 in general payments during 2025 across 44 reported records.
ABBVIE INC. accounted for 52.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $327.37 | 52.1% | 23 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $187.54 | 29.9% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.11 | 5.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.62 | 4.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.01 | 3.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.43 | 2.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.04 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $628.12 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $206.33 | 18 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $112.22 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $112.22 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $102.13 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $102.13 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $85.41 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.11 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $37.11 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.43 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $11.92 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $8.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
113 | 16 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 600 | 129 |
| Atorvastatin Calcium | Atorvastatin Calcium | 405 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 369 | 91 |
| Losartan Potassium | Losartan Potassium | 334 | 81 |
| Omeprazole | Omeprazole | 265 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 253 | 67 |
| Lisinopril | Lisinopril | 217 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 189 | 48 |
| Gabapentin | Gabapentin | 178 | 47 |
| Simvastatin | Simvastatin | 174 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 167 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 148 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 145 | 15 |
| Trazodone Hcl | Trazodone Hcl | 139 | 35 |
| Metformin Hcl Er | Metformin Hcl | 137 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 24 |
| Famotidine | Famotidine | 130 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 118 | 23 |
| Tramadol Hcl | Tramadol Hcl | 118 | 22 |
| Furosemide | Furosemide | 115 | 28 |
| Metformin Hcl | Metformin Hcl | 114 | 28 |
| Ozempic | Semaglutide | 113 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 28 |
| Potassium Chloride | Potassium Chloride | 102 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 23 |
| Eliquis | Apixaban | 91 | 18 |
| Sertraline Hcl | Sertraline Hcl | 91 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 25 |
| Montelukast Sodium | Montelukast Sodium | 87 | 25 |
| Lorazepam | Lorazepam | 85 | 26 |
| Spironolactone | Spironolactone | 79 | 23 |
| Donepezil Hcl | Donepezil Hcl | 76 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 74 | 14 |
| Allopurinol | Allopurinol | 72 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 66 | 18 |
| Propranolol Hcl | Propranolol Hcl | 66 | 12 |
| Atenolol | Atenolol | 64 | 18 |
| Meloxicam | Meloxicam | 64 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 11 |
| Methocarbamol | Methocarbamol | 63 | 14 |
| Memantine Hcl | Memantine Hcl | 62 | 12 |
| Ondansetron Odt | Ondansetron | 61 | 13 |
| Celecoxib | Celecoxib | 58 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 14 |
| Pregabalin | Pregabalin | 56 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | suppressed |
| Clonazepam | Clonazepam | 51 | suppressed |
| Myrbetriq | Mirabegron | 51 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 49 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | suppressed |
| Jardiance | Empagliflozin | 48 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 23 |
| Carvedilol | Carvedilol | 46 | suppressed |
| Ezetimibe | Ezetimibe | 44 | suppressed |
| Januvia | Sitagliptin Phosphate | 44 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 14 |
| Prednisone | Prednisone | 44 | 32 |
| Bupropion Xl | Bupropion Hcl | 43 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 43 | suppressed |
| Torsemide | Torsemide | 43 | suppressed |
| Cephalexin | Cephalexin | 42 | 28 |
| Ibuprofen | Ibuprofen | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Glipizide | Glipizide | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 36 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 36 | 11 |
| Linzess | Linaclotide | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 15 |
| Digoxin | Digoxin | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 23 |
| Finasteride | Finasteride | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 16 |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 14 |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Mupirocin | Mupirocin | 25 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Nystatin | Nystatin | 23 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | 13 |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 13 |
| Glimepiride | Glimepiride | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Emgality Syringe | Galcanezumab-Gnlm | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Butrans | Buprenorphine | 11 | suppressed |
| Efavirenz | Efavirenz | 11 | suppressed |
| Galafold | Migalastat Hcl | 11 | suppressed |
| Lamivudine-Zidovudine | Lamivudine/Zidovudine | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $628.12 · 44 records | ABBVIE INC. | EVENITY, Korlym, MAVYRET, NURTEC ODT, OTEZLA, PROLIA, QULIPTA, REPATHA, REXULTI, UBRELVY, VRAYLAR, Veozah, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error